Molecular Partners: Pipeline Momentum and Early Safety Data Support Unchanged $12 Price Target and Buy Rating
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Charles Zhu maintains a Buy rating and $12 price target for Molecular Partners. The recommendation is supported by disciplined pipeline execution, reassuring early safety data for lead asset MP0712 showing no dose-limiting toxicities, and expanding platform value from MP0726 and the new CD70 program. With favorable pipeline momentum relative to valuation, the analyst views the current outlook as positive.
Molecular Partners, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on the stock and has a $12.00 price target.
Charles Zhu has given his Buy rating due to a combination of factors, including disciplined execution across Molecular Partners’ radio-oncology pipeline and reassuring early safety data for lead asset MP0712. The company is progressing through dose escalation with no dose-limiting toxicities, manageable Grade 1–2 adverse events, and stable liver and kidney function markers, supporting continued clinical development at higher planned doses.
Zhu also cites the expanding platform value from MP0726 and the newly disclosed CD70 program in kidney cancer, which targets an antigen with high tumor expression and limited healthy tissue presence. With initial MP0712 data expected in 2026, a more complete safety and efficacy readout in 2027, and additional first-in-human work and IND-enabling studies underway, he views the pipeline momentum as favorable relative to current valuation, justifying an unchanged $12 price target and a Buy recommendation.